694 related articles for article (PubMed ID: 24217510)
1. Alzheimer disease therapy--moving from amyloid-β to tau.
Giacobini E; Gold G
Nat Rev Neurol; 2013 Dec; 9(12):677-86. PubMed ID: 24217510
[TBL] [Abstract][Full Text] [Related]
2. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
Boutajangout A; Wisniewski T
Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
4. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
5. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
Wilcock DM; Gharkholonarehe N; Van Nostrand WE; Davis J; Vitek MP; Colton CA
J Neurosci; 2009 Jun; 29(25):7957-65. PubMed ID: 19553436
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
7. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
Suzuki N; Hatta T; Ito M; Kusakabe KI
Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
[TBL] [Abstract][Full Text] [Related]
8. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
9. Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade.
Gulisano W; Maugeri D; Baltrons MA; Fà M; Amato A; Palmeri A; D'Adamio L; Grassi C; Devanand DP; Honig LS; Puzzo D; Arancio O
J Alzheimers Dis; 2018; 64(s1):S611-S631. PubMed ID: 29865055
[TBL] [Abstract][Full Text] [Related]
10. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
Bakota L; Brandt R
Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
[TBL] [Abstract][Full Text] [Related]
11. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
12. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
Bloom GS
JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
[TBL] [Abstract][Full Text] [Related]
14. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
[TBL] [Abstract][Full Text] [Related]
15. p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.
Walls KC; Ager RR; Vasilevko V; Cheng D; Medeiros R; LaFerla FM
Neurosci Lett; 2014 Jul; 575():96-100. PubMed ID: 24887583
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β-independent regulators of tau pathology in Alzheimer disease.
van der Kant R; Goldstein LSB; Ossenkoppele R
Nat Rev Neurosci; 2020 Jan; 21(1):21-35. PubMed ID: 31780819
[TBL] [Abstract][Full Text] [Related]
17. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Long JM; Holtzman DM
Cell; 2019 Oct; 179(2):312-339. PubMed ID: 31564456
[TBL] [Abstract][Full Text] [Related]
19. Synergy between amyloid-β and tau in Alzheimer's disease.
Busche MA; Hyman BT
Nat Neurosci; 2020 Oct; 23(10):1183-1193. PubMed ID: 32778792
[TBL] [Abstract][Full Text] [Related]
20. Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease.
Takata K; Kitamura Y; Nakata Y; Matsuoka Y; Tomimoto H; Taniguchi T; Shimohama S
Am J Pathol; 2009 Jul; 175(1):17-24. PubMed ID: 19497998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
